Trials / Completed
CompletedNCT00202982
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to test if a new higher dose of Copaxone is more effective in treating relapsing-remitting multiple sclerosis than the currently available 20 mg dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glatiramer acetate 20 mg | glatiramer acetate 20 mg |
| DRUG | glatiramer acetate 40 mg | glatiramer acetate 40 mg |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2005-09-20
- Last updated
- 2010-01-14
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00202982. Inclusion in this directory is not an endorsement.